Abstracts tagged "death"

Abstract Number: 1089 • 2019 ACR/ARP Annual Meeting
Causes of Death in ANCA-Associated Vasculitis According to ANCA Type
Zachary Wallace¹, Xiaoqing Fu ¹, Tyler Harkness ¹, John Stone ², Yuqing Zhang ³ and Hyon K. Choi ³, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: Survival has improved in ANCA-associated vasculitis (AAV) with evolving management strategies, but patients remain at an increased risk of death compared to the general…
Abstract Number: 941 • 2018 ACR/ARHP Annual Meeting
Causal Inference Methods for the Effect of Rheumatoid Arthritis on Mortality Independent of Lifestyle and Clinical Factors before and after RA Diagnosis
Jeffrey A. Sparks¹, Kazuki Yoshida^1,2, Tzu-Chieh Lin³, Carlos Camargo⁴, Benjamin Raby⁵, Hyon K. Choi⁶, Medha Barbhaiya⁷, Sara K. Tedeschi¹, Bing Lu⁸, Karen Costenbader¹ and Elizabeth Karlson¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Harvard T.H. Chan School of Public Health, Boston, MA, ³Amgen, Thousand Oaks, CA, ⁴Emergency Medicine, Massachusetts General Hospital, Boston, MA, ⁵Pulmonary, Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: RA is associated with increased total, cardiovascular, and respiratory mortality compared to the general population. This excess RA mortality may be mediated through lifestyle,…
Abstract Number: 1515 • 2018 ACR/ARHP Annual Meeting
Malignancy in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim Analysis of All-Case Post-Marketing Surveillance
Naoto Tamura¹, Masataka Kuwana², Tatsuya Atsumi³, Syuji Takei⁴, Masayoshi Harigai⁵, Takao Fujii⁶, Hiroaki Matsuno⁷, Tsuneyo Mimori⁸, Shigeki Momohara⁹, Kazuhiko Yamamoto¹⁰, Yoshinari Takasaki¹¹, Kazuto Nomura¹², Yutaka Endo¹², Tomohiro Hirose¹², Yosuke Morishima¹², Naonobu Sugiyama¹², Noritoshi Yoshii¹² and Michiaki Takagi¹³, ¹Juntendo University, Tokyo, Japan, ²Nippon Medical School, Tokyo, Japan, ³Hokkaido University, Sapporo, Japan, ⁴Medical Center for Children, Kagoshima, Japan, ⁵Tokyo Women’s Medical University, Tokyo, Japan, ⁶Wakayama Medical University, Wakayama, Japan, ⁷Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ⁸Kyoto University, Kyoto, Japan, ⁹Hakkeikai Inc Medical Institution, Shizuoka, Japan, ¹⁰The University of Tokyo, Tokyo, Japan, ¹¹Juntendo Koshigaya Hospital, Juntendo University Faculty of Medicine, Saitama, Japan, ¹²Pfizer Japan Inc, Tokyo, Japan, ¹³Yamagata University Faculty of Medicine, Yamagata, Japan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The efficacy and safety of tofacitinib have been demonstrated in patients (pts)…
Abstract Number: 1844 • 2018 ACR/ARHP Annual Meeting
Racial Disparities and Accelerated SLE Mortality from a Population-Based Registry: The Georgia Lupus Registry
S. Sam Lim¹, Charles G. Helmick², Gaobin Bao³, Caroline Gordon⁴, Jennifer M. Hootman² and Cristina Drenkard⁵, ¹Emory University School of Medicine, Atlanta, GA, ²Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ³Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁴Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁵Medicine/Rheumatology, Emory University, Atlanta, GA
Background/Purpose: Population-based SLE mortality studies have depended on administrative data from vital statistics records to identify cases. However, a high proportion of SLE deaths have…
Abstract Number: 1888 • 2018 ACR/ARHP Annual Meeting
SLE Among the Leading Causes of Years of Potential Life Lost in Young Women: Population-Based Study, 2000-2015
Eric Yen and Ram R. Singh, UCLA, Los Angeles, CA
Background/Purpose: Ten-year survival of SLE has improved from <50% in the 1950s to ~95% in the 2000s. However, the relative and true disease burden for…
Abstract Number: 2803 • 2018 ACR/ARHP Annual Meeting
48-Year Trends in Systemic Sclerosis Mortality in the United States, 1968-2015: Steady Decrease for 15 Years after 33 Years of Continuous Increase
Eric Yen, Devanshu Singh and Ram R. Singh, UCLA, Los Angeles, CA
Background/Purpose: A comprehensive evaluation of long-term trends in systemic sclerosis (SSc) mortality is important to understand the influence of recent advances in SSc management and…
Abstract Number: 2982 • 2018 ACR/ARHP Annual Meeting
Normal Mortality of the Cobra Early Rheumatoid Arthritis Trial Cohort after 23 Years Follow up
Pomme Poppelaars¹, Lilian van Tuyl² and Maarten Boers^1,3, ¹Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, ³Epidemiology & Biostatistics, Epidemiology & Biostatistics | VU University Medical Center, Netherlands, Amsterdam, Netherlands
ACR abstractBackground/Purpose: Mortality in patients with rheumatoid arthritis (RA) is higher than in the general population. In most studies this becomes apparent only after more…
Abstract Number: 840 • 2017 ACR/ARHP Annual Meeting
Mortality Post Hip Fracture in Rheumatoid Arthritis Compared to General Population Controls, a Population-Based Study
C. Allyson Jones¹, Pierre Guy², Hui Xie³, Eric C. Sayre⁴ and Diane Lacaille^5,6, ¹Physical Therapy, University of Alberta, Edmonton, AB, Canada, ²Department of Orthopaedics, University of British Columbia / Centre for Hip Health and Mobility, Vancouver, BC, Canada, ³Biostatistics, Faculty of Health Sciences, Simon Fraser University / Arthritis Research Canada, Burnaby, BC, Canada, ⁴Arthritis Research Canada, Richmond, BC, Canada, ⁵University of British Columbia, Arthritis Research Canada, Richmond, BC, Canada, ⁶Arthritis Research Canada/ University of British Columbia, Vancouver, BC, Canada
Background/Purpose: In prior work, we found a higher incidence of hip fractures in RA than age and sex matched general population controls (4.1 vs. 2.9…
Abstract Number: 987 • 2017 ACR/ARHP Annual Meeting
Death Certificates Do Not Accurately Identify SLE Patients
Kelly Kaysen, Cristina Drenkard, Gaobin Bao and S. Sam Lim, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Mortality rates are higher in SLE patients compared to the general population, and research on SLE mortality is ongoing. The majority of mortality studies…
Abstract Number: 1429 • 2017 ACR/ARHP Annual Meeting
Incidence Rates of Adverse Events with Death As an Outcome during Abatacept Treatment in RA: Results from an Integrated Data Analysis from 16 Clinical Trials
D Fleming¹, TA Simon¹, A Torbeyns², U Meier-Kriesche¹ and A Johnsen¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Braine l’Alleud, Belgium
Background/Purpose: Patients with RA have a 1.5–2-fold increased risk of mortality compared with the general population. The association between mortality rates and different RA treatments…
Abstract Number: 1804 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes and Damage Predict Mortality in Lupus
Desiree R Azizoddin¹, Meenakshi Jolly², Patricia P. Katz³ and Edward H. Yelin⁴, ¹Department of Psychology, Loma Linda University, Loma Linda, CA, ²Rush, Chicago, IL, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Physician-assessed disease activity and damage predict mortality in systemic lupus erythematosus (SLE). Patient-reported outcomes (PROs) are known predictors of mortality in other chronic diseases,…
Abstract Number: 2846 • 2017 ACR/ARHP Annual Meeting
Cause-Specific Mortality in Gout: Novel Findings of Elevated Risk of Renal-Related and Decreased Risk of Dementia-Related Death
Ana Beatriz Vargas-Santos¹, Tuhina Neogi², Geraldo Castelar-Pinheiro¹ and Aleksandra Turkiewicz³, ¹Internal Medicine - Rheumatology, State University of Rio de Janeiro, Rio de Janeiro, Brazil, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Clinical Sciences Lund, Orthopedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden
Background/Purpose: There is recognized higher mortality among gout patients, with cardiovascular (CV) mortality having been previously reported. The present study aimed to examine cause-specific mortality…
Abstract Number: 203 • 2016 ACR/ARHP Annual Meeting
Allopurinol Dose Escalation and Mortality Among Patients with Gout: A National Propensity-Matched Cohort Study
Brian W Coburn^1,2, Kaleb Michaud³, Debra A Bergman² and Ted R Mikuls^4,5, ¹Research Service, Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, NE, ²Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁴Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

Allopurinol Dose Escalation and Mortality among Patients with Gout: A National Propensity-Matched Cohort Study Background/Purpose: Numerous epidemiologic studies show that hyperuricemia and gout are associated…
Abstract Number: 993 • 2016 ACR/ARHP Annual Meeting
Chronic Widespread Pain Associated with Premature Mortality in a UK National Prospective Study
Gary J. Macfarlane^1,2 and Gareth T. Jones^3,4, ¹Epidemiology Group, University of Aberdeen, Aberdeen, United Kingdom, ²Aberdeen Centre for Arthritris and Musculoskeletal Health, University of Aberdeen, Aberdeen, United Kingdom, ³Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, United Kingdom, ⁴Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom
Background/Purpose: A small number of studies have examined the long-term consequences of having chronic widespread pain (CWP). Most report premature mortality, but the magnitude and…
Abstract Number: 2794 • 2016 ACR/ARHP Annual Meeting
Sustained Complete Remission in Lupus Nephritis
Rattapol Pakchotanon¹, Dafna D. Gladman², Jiandong Su² and Murray Urowitz³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The durability of renal remission might be a predictor of good long-term renal outcome and survival in patients with lupus nephritis (LN). We aimed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].